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Abstract: Metastatic disease is the major challenge of cancer that accounts for over 90% of total cancer 
lethality. Mounting clinical and preclinical data now indicate that inflammation, a potent immune and 
repair response, is indispensable for metastasis. In this review we describe our current understanding of 
how major inflammatory cells contribute to metastatic cascade with a focus on the primary tumour. We 
also discuss exciting new directions for future research and novel therapeutic approaches to tackle 
metastatic disease through targeting inflammation. 
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Introduction 
Inflammation is a response that an organism uses to resolve infection, tissue injury or other cellular stress, 
and to restore tissue function through repair mechanisms [1]. It is a sophisticated process involving 
extensive crosstalk among different immune cells as well as non-immune cells, such as epithelial cells, 
endothelial cells and fibroblasts. Unlike normal tissue, cancer involves continuous cell renewal and 
proliferation that induces persistent inflammation [2]. In fact, inflammation is observed in almost every 
cancer and is one of the hallmarks of cancer [3]. Cancer associated inflammation involves crosstalk 
between both malignant and nonmalignant cells through mediators (e.g. cytokines, chemokines and 
prostaglandins) in autocrine and paracrine manner [4]. Joint forces with genetic alteration, the 
inflammatory tumour environment eventually leads to tumor progression and metastasis [5]. For example, 
inflammatory response associated with epithelial cell senescence contributes significantly to 
transformation and carcinogenesis in the absence of p53 tumour suppressor gene, which can be inhibited 
with anti-inflammatory drugs [6]. Treatment with the anti-inflammatory drug dexamethasone also 
significantly suppressed cancer dissemination through suppression of epithelial to mesenchymal transition 
(EMT), a process epithelial cell uses to obtain migratory and invasive properties [7]. Thus, inflammation is 
an indispensable driver for cancer metastasis.  
 
Mechanistically, tumour associated inflammation produces mutagenic factors (e.g. reactive oxygen 
species) that drive tumour initiation[5]. Tumour associated inflammation is a source of survival, growth 
and pro-angiogenic factors, as well as extracellular matrix (ECM)-modifying enzymes that facilitate 
angiogenesis, invasion and metastasis [8, 9]. Inflammation induced angiogenesis not only provides 
necessary nutrients for tumour growth, but also provides a ‘highway’ for tumour to escape from the 
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primary tumour site to start their journey of distal metastasis. Inflammation is also associated with 
suppression of anti-tumour immune responses. This leads to tumour escaping from host immune 
surveillance that is essential for almost all steps of metastatic tumour progression [10, 11]. This review will 
discuss major host cell types involved in inflammation and their contribution to cancer metastasis with a 
focus on the series of events that enables tumour cells to escape from the primary tumour including 
angiogenesis, ECM remodeling, immune suppression, invasion and intravasation (Figure 1). 
 
Macrophages 
Macrophages are powerful regulators of inflammation[12, 13]. They are often the most abundant immune 
cells infiltrating the tumour and their infiltration is associated with poor prognosis and treatment 
failure[14]. These tumour-associated macrophages (TAMs) play multiple roles in promoting cancer 
metastasis.  
 
Macrophages potently promote tumour angiogenesis that contributes significantly to metastasis. Initial 
experimental evidence comes from in vivo studies using Polyoma middle T antigen (PyMT) onco-protein 
induced mouse mammary tumour model. In this model, macrophage deficiency through genetic ablation 
of colony stimulating factor 1 (CSF1), the major lineage growth factor, significantly inhibited angiogenesis 
[15] and distal metastasis [16, 17]. Part of the mechanism may act through macrophage derived angiogenic 
factors including vascular endothelia growth factor VEGF [18]. Transcription factor Ets2 in TAMs acted 
downstream of the CSF1 signaling that promote PyMT breast cancer lung metastases at least partly by 
promoting angiogenesis in the primary tumours [19]. Furthermore, macrophage derived Wnt7b is critical 
for angiogenic switch in the PyMT primary tumours and macrophage specific genetic depletion of which 
significantly inhibited lung metastasis [20]. In Lewis lung carcinoma model, interleukin 1 alpha (IL-1a) 
expressed by cancer cells can induce the recruitment of cyclooxygenase 2 (COX2)-expressing macrophages 
that in turn secretes inflammatory cytokines to promote tumor angiogenesis and metastatic progression 
[21]. Reciprocally, new blood vessels secrete angiopoietin 2 to recruit macrophages expressing TEK 
receptor tyrosine kinase (also known as Tie2) to further promote angiogenesis and tumour dissemination 
from the primary tumour [22]. IL-1b expression by myeloid cells has also been shown to induce VEGF 
expression in endothelial cells that promote angiogenesis, inflammation and tumour progression [23].  
 
Macrophages also actively remodels extra-cellular matrix (ECM) through production of extra-cellular 
proteinases, such as MMPs and cathepsins. ECM remodeling together with the release of ECM binding 
cytokines promote angiogenesis, inflammatory cells infiltration and tumour cell invasion. For example, 
TAM derived cathepsin B and cathepsin S can promote cancer cell egress and angiogenesis [24]. Matrix 
metalloproteinase 9 (MMP9) derived from TAMs together with other myeloid cells is important for skin 
cancer progression [25]. In pancreatic islet cancer models, myeloid cell derived MMP2 and MMP9 
modulate the ECM and release VEGF from ECM that enhances angiogenesis [26]. TAMs also promote 
tumour cell interaction with ECM through secretion of Secreted Protein Acidic and Rich in Cysteine (SPARC, 
also known as osteonectin). This interaction is dependent on tumour cell alpha(v)beta(5) integrin, which 
contribute significantly to tumour invasion and metastasis [27]. Interestingly, TAMs are able to modulate 
tumour cell integrin clustering and enhancing its adherence to extracellular matrix through the secretion of 
CCL18, which promotes invasion and metastasis [28]. Interaction with ECM can regulate macrophages’ 
own function. Versican (VCAN), a extracellular matrix protein secreted by Lewis lung carcinoma cell, 
interact with Toll like receptor 2 and 6 on macrophages to induce expression of inflammatory cytokines IL6 
and TNFa which is critical for tumour metastasis in lung[29]. Consistently, VCAN promotes macrophage 
infiltration and lung metastasis in a mouse model of invasive bladder cancer. Macrophage ablation in this 
model significantly decreased lung metastases and the levels of COX2 and inflammatory factors IL-6, CCL2 
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in the tumor microenvironment [30]. Together, these results indicate that the interaction among TAMs, 
tumour cells and ECM significantly promotes tumour cells escape from primary tumour.  
 
Macrophages have been shown to interact with tumour cells directly to promote their invasion into the 
surrounding tissue and intravasation. Using intra-vital imaging, Wyckoff and colleagues showed that cancer 
cells in PyMT tumours invade surrounding tissues together with TAMs [31]. In this process, cancer cells 
secrete CSF1 to promote TAM mobility. In turn, TAMs secrete epidermal growth factor (EGF) to activate 
the corresponding receptor on cancer cells that enhances their motility and invasive potential by 
increasing invadopodium formation and matrix degradation[32]. Mechanistically, CSF1 receptor (CSF1R) in 
macrophages activates Wiskott–Aldrich syndrome protein (WASP) to promote TAM migration towards 
CSF1-producing cancer cells and stimulates EGF release [33]. Tumour cell CSF1 production is dependent on 
steroid receptor co-activator 1 (SRC1) which when genetically deleted disrupts the paracrine signaling 
between tumour cell and TAMs. This significantly inhibited tumour cell invasion in PyMT tumours and 
subsequent lung metastasis without affecting primary tumour growth[34]. Interestingly, macrophage-
tumour cell paracrine signaling can also be established through macrophage derived heregulin β1 (HRGβ1) 
and tumour cell derived CXCL12 that triggers tumour invasion [35]. In human breast cancer xenograft 
models, paracrine signaling of CCL18 and GM-CSF derived from macrophage and tumour cell respectively 
induces macrophage polarization, tumour cell migration and subsequent metastasis[36]. Recent studies 
also illustrated that macrophage secreted factors stimulate S100A8 and S100A9 expression in colon cancer 
cells that promoted their invasion and liver metastasis [37]. Thus, depending on tumour types, multiple 
signaling pathways can be hijacked by tumour cells to interact with TAMs to achieve invasion and 
metastasis.  
 
Tumour cell intravasation has been reported to occur in association with perivascular TAMs in breast 
cancer models [38]. This seems to be associated with a micro anatomic structure within the tumour, which 
is composed of direct interacting macrophage, endothelia and invasive tumour cell (termed as ‘tumour 
microenvironment for metastasis or TMEM’) [39]. Regardless of clinical subtypes or tumour grade, TMEM 
abundance in breast cancer specimens correlates with tumour cell expression of the invasive isoform of 
MENA (an actin binding protein essential for chemotactic direction and invasion) [40]. This significantly 
potentiates EGF signaling in cancer cells [41] and promotes macrophage-induced intravasation of human 
breast cancer cells [39]. Using intra-vital microscopy, our recent studies indeed illustrated that the TMEM 
structure control tumour cell intravasation by transiently increase local vascular permeability in a VEGF 
dependent manner [42]. Importantly, the abundance of TMEM has been shown to predicate metastasis of 
ER+ breast cancer in a case control study with over 3700 patient samples [43]. Together, these data 
strongly indicate that tumour-macrophage crosstalk plays a central role in promoting tumour cell 
intravasation. Whether this mechanism is commonly used across different tumour types and whether 
TMEM can be used as prognostic marker for other cancers will be topics of great interests for future 
research.  
 
The metastasis promoting function of TAM is tightly regulated by the inflammatory tumour 
microenvironment. TAM recruitment into tumour hypoxia area is partly mediated by neuropilin 1 (Nrp1), 
that binds to Semaphorin-3A (SEMA3A). Disruption of this signaling significantly suppresses the pro-
angiogenic function of TAMs and inhibits tumour progression and lung metastasis [44]. Interleukin 1 
receptor activation is observed in patients with renal cell carcinoma (RCC) and is essential for TAM 
phenotype and function in RCC xenograft models that promotes tumour angiogenesis and invasion [45]. 
Inhibitor of cyclooxygenase 2 (COX2) the enzyme that generates inflammatory factor prostaglandin, 
significantly suppresses VEGF expression in TAMs and inhibits breast cancer metastasis [46]. Furthermore, 
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TAM polarization can be skewed from a pro-tumorigenic to an anti-tumour phenotype by altering the 
signals in the tumour microenvironment. For example, overexpression of histidine-rich glycoprotein (HRG) 
can down-regulate placental growth factor (PlGF) expression and alter TAM polarization. This normalizes 
the leaky blood vessels and inhibits metastasis [47]. Inhibition of CSF1 receptor signaling alters TAM 
polarization in GEM models of Glioblastoma multiforme, which leads to dramatic tumour regression [48]. 
Together, these studies indicate that signaling pathways regulating TAM functions can be promising 
therapeutic targets to treat advanced tumour. 
 
Other myeloid cells 
Neutrophils. Neutrophils may contribute to metastatic disease. Elevated neutrophil number in blood is 
associated with increased metastasis risk of many solid tumours [49]. A large-scale meta-analysis indicated 
that intra-tumoural neutrophil-related gene signature is associated with poor prognosis [50]. Indeed, a 
recent study showed that neutrophil infiltration in a genetically engineered mouse model of melanoma 
enhanced tumour migration and invasion resulting in distal metastasis. This neutrophil infiltration was 
mediated by high mobility group protein B1 (HMGB1) derived from the ultraviolet UV-damaged 
keratinocytes, which illustrated a novel mechanism of UV induced inflammation in melanoma metastasis 
[51]. Consistently, granulocytic immature myeloid cells overexpressing S100A9 proteins, a key 
inflammation regulator, have been shown to promote tumour formation in models of skin cancer [52]. 
Neutrophils recruited by tumour-derived CXCL15 have been shown to promote lung metastasis in a 
xenograft model of intrahepatic cholangiocarcinoma [53]. Together these data indicate that neutrophils 
may promote tumour progression and escape from primary tumour with the models tested. 
 
Of note, neutrophils in the distal metastatic organ have been shown to have either pro- or anti- metastatic 
functions [54-57]. This suggests that the phenotype and function of neutrophils are tightly regulated by 
specific environmental factors [58]. Further studies are required to test the role of neutrophils in primary 
tumour across different cancer types and if their anti-metastatic function can be elicited by altering signal 
from the inflammatory microenvironment. 
 
Myeloid derived suppressor cells (MDSCs) MDSCs have been defined as CD11b+Gr1+ immature myeloid 
cells that have the potential to inhibit immune response [59, 60]. Direct evidence that MDSCs promote 
metastasis was initially shown in the PyMT mouse mammary tumour model [61]. In this study, abrogation 
of TGFβ signaling in tumour cells leads to chemokine CXCL5 expression and MDSC recruitment which 
promote tumour cell invasion through MMPs. Recent studies indicate the recruitment of MDSCs may be 
also mediated by G-CSF expression in cancer cells dictated by mTOR signaling [62]. However, MDSCs are a 
heterogeneous population of cells with distinct morphology and cell surface expression of the lymphocyte 
antigens LY6C and LY6G. The subsets are termed monocytic MDSCs (CD11b+Ly6ChiLy6Glow cells) and 
granulocytic MDSCs (CD11b+LY6ClowLY6G+ cells) [63]. Essentially, the cell surface markers of monocytic 
MDSCs and granulocytic MDSCs are identical to monocytes and neutrophils. Both subsets in mice suppress 
immune effector cell function by nitric oxide synthase (iNOS) and arginase 1 [63]. Furthermore, monocytic 
MDSCs have been shown to give rise to granulocytic MDSCs [64]. Thus caution needs to be excised to 
dissect the contribution of each population and mature macrophages that can be derived from monocytes 
to metastasis in various tumour models. 
 
Lymphocytes 
T cell T cell is a type of lymphocyte that matures in thymus and characterized by T cell receptor expression. 
It contains many subsets. CD8+ cytotoxic T cell (CTL) is the subset that plays a central role in cell-mediated 
immunity. Its cytotoxicity is also key to anti-tumour immune surveillance that would inhibit every step of 
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cancer metastasis. CTLs are usually suppressed in advanced cancers and re-activation of their function is 
the focus of current immune therapy that exhibited great promises in treating metastatic cancer [65].    
 
CD4+ T helper (Th) cells are highly heterogeneous in regulating inflammation. Earlier studies characterized 
two major populations of Th cells: Th1 and Th2 characterized by expression of Type 1 cytokine (e.g. 
interferon-gamma, IFNΥ, tumor necrosis factor-alpha, TNFa and interleukine-2, IL-2) and Type 2 cytokine 
(e.g. IL4, IL10) respectively. Th1 response activates CTLs and other cytotoxic cells, thus is being used in 
clinical trials of cancer immunotherapies including therapeutic vaccines[66]. In contrast, Th2 cell activity 
leads to humoral immunity and inflammation that may promote tumour progression[67]. Via IL4 
expression, CD4+ T helper cells have been shown to induce alternative activation of TAMs and secretion of 
EGF that directly promote tumour invasion and egress from primary tumour [68]. This IL4 expression may 
also be responsible for the expression of Cathepsins [24] and CCL18 [28] in TAMs that promote tumour 
progression and invasion. CD4+ T helper cells contain several subsets. Regulatory T cells (or Treg cells) are 
the subset characterized by expression of Forkhead box P3 (Foxp3) transcription factor and their potent 
function in suppressing inflammation and immune response [69]. Suppression mechanisms employed by 
Tregs are thought to contribute significantly to the inhibition of T-cell immunity to tumour-associated 
antigens, which is prerequisite for cancer metastasis[70, 71]. IL-17–producing CD4+ T cells, also known as 
Th17 cells, are a pro-inflammatory subset involved in autoimmune and inflammatory disorders [72]. Th17 
mediated inflammation promoted tumour initiation in multiple models of skin carcinogenesis [73, 74]. 
Human CD25high Th17 cells are highly infiltrated in human breast cancers with poor clinical outcome where 
these cells seem to suppress CTL mediated anti-tumour immunity [75]. Interestingly, breast cancer induced 
systemic inflammation can activate IL17 expression that promotes spontaneous metastasis through 
granulocyte colony-stimulating factor (G-CSF)-dependent neutrophil activation and immune 
suppression[54]. IL17 has also been shown to promote colorectal tumorigenesis[76, 77]. However, IL17 has 
also been reported to inhibit tumour growth through T cell dependent mechanisms[78]. The abundance of 
IL17 expressing cells in colon cancer patient samples has recently been shown to be associated with 
improved survival potentially through recruitment of cytotoxic CD8+ T cells [79]. Of note, there are other 
types of T helper cells that are being characterized recently, such as γδ T cells, Th9, Th22, follicular T helper 
cells etc. Their roles in inflammation and cancer are just starting to be realized [80, 81] while their role in 
metastasis is still illusive. Further studies should focus on dissecting the positive or negative roles different 
T helper cell populations in metastasis in different tissue environment and tumour stages.  
 
B cell Cells of B lymphocyte lineage have been shown to promote or inhibit inflammation [82-84]. B cells 
may contribute to squamous carcinogenesis by alternatively activating macrophages via immune complex 
deposition[85] and by suppressing T-cell–mediated antitumor response[86]. Several recent studies 
illustrated important roles of B-lymphocytes in tumour progression and therapy responses in pancreatic 
cancer models [87-89]. Gunderson and colleagues demonstrated that B cells mediated inflammation 
induces TAM alternative activation and tumour progression of advanced PDAC in an Fc receptor gamma 
(FcRγ) dependent manner[89]. In early pancreatic neoplasia, B cells are required to support tumour growth 
through IL35 production[88]. B1 cells are considered to be a type of innate immune cells of B cell lineage 
that produce the majority of natural antibodies against infections. Interestingly, Lee and colleagues 
reported an increase of CD43+IgMhiCD5− B1 cells in mouse pancreatic neoplastic lesions. This subset of B1-
cells seems to be controlled by oxygen-sensing mechanisms since pancreatic specific ablation of HIF1α 
further expand these cells and promote PDAC initiation[87]. Given the potent function of B cells in above 
discussed studies, it is likely that further studies may illustrate how B cell mediated inflammation may 
contribute directly to cancer metastasis. 
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Innate lymphoid cells (ILCs) ILCs are a group of innate immune cells that belong to the lymphoid lineage but 
do not respond in an antigen-specific fashion[90]. ILCs can be categorized based on their cytokine 
production and dependent transcription factors into three groups (1-3), mirroring the nomenclature of T 
cell subsets[91]. Group 1 ILCs including ILC1 and Natural Killer (NK) cells are characterized by expression of 
Th1 cytokines, typically IFNΥ. Group 2 ILCs express Th2 cytokines including interleukin-4 (IL4), IL5 and IL13. 
Group 3 ILCs are able to produce Th17 associated cytokines IL17 and IL22. Thus, these cells have specific 
functions in the inflammatory response in different organs [92].  
 
NK cells are distinct from other ILCs by their potent cytotoxic activity that lyses target cell directly via 
production of perforin, granzyme B and pro-inflammatory cytokines like IFNΥ. The identification of their 
anti-tumour role dates back several decades ago[93]. In tumour, NK cells also lyse tumour cells through 
activation of T cell function and /or antibody-dependent cell-mediated cytotoxicity. Thus, NK cell actively 
inhibit almost every step of tumour metastasis. For example, recent studies indicate that NK cells keep 
breast and lung cancer cells in quiescence in multiple metastatic organs [94]. The cytotoxic functions of NK 
cells are often suppressed by tumour cells and tumour microenvironment[95] including myeloid cells[63] 
and Tregs[96, 97]. Of note several approaches are being tested in clinic trials to re-activate NK cells to treat 
late stage or metastatic tumours. Similar to T cell checkpoint blockade therapies, antibody (Lirilumab) 
blocking of NK cell inhibitory receptors Killer-cell immunoglobulin-like receptors (KIRs) is currently being 
tested in clinical trials (ClinicalTrials.gov Identifier: NCT01714739). Inhibition of the TAM (Tyro3, Axl and 
Mer) tyrosine kinase receptors in NK cells may also potentiate their anti-metastatic potential[98]. Adoptive 
transfer of human NK cells pretreated cytokine cocktail of IL-12, IL-15 and IL-18 is currently being tested in 
patients with acute myeloid leukemia (ClinicalTrials.gov Identifier: NCT01520558). Autologous transfer of 
genetically-engineered NK cells with chimeric antigen receptor (CAR) are being explored to direct NK cell 
cytotoxicity more specifically toward cancer cells [99]. Thus, it is with hope that reactivation of anti-
metastasis activity of NK cells can soon lead to clinical benefit in the near future.   
 
Data on the role of other ILC populations in tumour are just emerging and indicating both tumour 
promoting and suppressing potentials of different populations. ILC1s have been reported to suppress 
tumour development in PyMT mouse mammary tumour models [100]. ILC2s have been shown to promote 
mammary tumour growth through IL-13 production and recruitment of myeloid cells and Tregs [101]. ILC3 
cells are involved in the homeostasis of gastrointestinal tract and suppression of bacteria-induced 
inflammation through IL-17 and/or IL-22 secretion. In contrast, in inflammatory bowel disease, ILC3 
derived IL-17 enhances the inflammatory response [102]. ILC3 derived pro-inflammatory cytokines can 
improve tumour progression in preclinical models of colon cancer and hepatocellular carcinoma [103]. ILC3 
cells are also involved in the development of human non-small cell lung cancer by modulating the tumour 
microenvironment [104]. Thus innate lymphoid cells may play important roles in the inflammatory 
environment of cancer metastasis. 
 
Mesenchymal cells 
Inflammation research has largely been focusing on immune cells in the past. Recent studies indicate that 
cells of mesenchymal origin, most notably mesenchymal stem cells (MSCs) and fibroblasts are important 
regulators of inflammatory response [105, 106]. MSCs have potent immune suppressive functions through 
multiple mechanisms including inducible nitric oxide synthase (iNOS), indolea- mine 2,3-dioxygenase (IDO), 
PGE2, IL-10, hemeoxygenase-1 (HO-1), programmed cell death 1 ligand 1 (PD-L1) and IL-6[107]. For 
example, human MSCs can inhibit dendritic cell differentiation and pro-inflammatory cytokine 
expression[108]. MSC derived PGE2 can inhibit DC maturation, reprogram macrophages to release IL10, 
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and switch the Th1 response to a Th2 response [109]. MSCs can also recruit immune suppressive 
macrophages to promote tumour growth through CCL2 secretion [110].  
 
As the most abundant mesenchymal cells in tumour, cancer associated fibroblasts (CAFs) share many 
features as fibroblasts involved in wound healing and actively modulate tumour microenvironment[111]. 
CAF mediated inflammatory response can promote macrophage recruitment, angiogenesis and tumour 
progression in an NF-kB signaling dependent manner in skin cancer models [112].  CAF derived pro-
inflammatory factors have also been shown to promote breast cancer progression [113]. Furthermore, 
MSCs and CAFs can promote metastasis through direct interaction with tumour cells. For example, bone 
marrow derived MSCs can be recruited by CXCL16/CXCR6 chemokine signaling into prostate cancer in vivo 
and differentiate into CAFs. These CAFs in turn promote prostate tumour cell invasion and metastasis 
through production of CXCL12 [114, 115] and CCL5 [116]. Consistently, CAFs can promote colorectal cancer 
cell intravasation and distal metastases through the secretion of stanniocalcin 1 (STC1) [117]. Future 
research is needed to better understand the direct interaction of MSC and its progenies with immune cells 
in modulating the inflammatory environment in cancer metastasis. 
 
Of note, both MSCs and CAFs have been shown to promote tumour metastasis through their potent 
function in ECM remodeling. For example, MSCs have been shown to promote invasion of ovarian cancer 
cells through MMP2 and MMP9[118]. CAF is a rich source of MMPs that promote ECM remodeling and 
tumour cell invasion [119]. CAF have also been shown to generate mechanical pressure together with 
paracrine signaling that potently promote tumour invasion and metastasis [120]. These activities have 
been reviewed extensively recently [111] and are mostly independent of inflammation thus go beyond the 
scope of current review.  
 
Conclusion 
In general, inflammatory response has been hijacked by tumour cells to serve as a driving force for tumour 
metastasis. However, various inflammatory cells have anti-tumour potentials that can be elicited by 
modulation of the cytokine environment and/or signaling pathway within these cells. This provides an 
attractive therapeutic strategy to effectively treat advanced cancer alone or in combination with existing 
therapeutic modalities. Of note, even in aggressive tumours, only minority of cancer cells are migratory as 
revealed by intra-vital imaging studies across multiple tumour models [121, 122]. This may be partly 
caused by tumour cell plasticity[123] and intrinsic heterogeneity[124]. However, mounting evidence now 
indicates that the inflammatory tumour microenvironment is also heterogeneous which may be associated 
with heterogeneous tumour cell behavior [122]. For example, cells that undergo EMT have been show to 
reside preferentially in the perivascular region [125]. Local ECM composition and macrophage association 
have been shown to determine tumour cell motility in vivo [126]. Thus heterogeneity of the inflammatory 
tumour environment may significantly contribute to cancer metastasis at single- or multiple-cell level. 
Future studies characterizing this microenvironmental heterogeneity are warranted to illustrate novel 
mechanisms of cancer metastasis and inspire effective new therapies to eradicate this deadly disease.  
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Figure 1. Inflammatory stroma in cancer egress from primary 
tumour: For haematogenous metastasis, the initial rate-limiting 
steps that allow cancer cells to escape from the primary site include 
(1) angiogenesis, (2) extracellular matrix (ECM) remodeling, (3) 
invasion and (4) intravasation. These processes are facilitated (-->) 
or inhibited (--I) by variety of stromal cell types involved in 
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regulating tumour inflammation. NK cell: natural killer cell; ILC: 
innate lymphoid cell; MDSC: myeloid derived suppressor cell; MSC, 
mesenchymal stem cell; CAF: cancer associated fibroblast; Treg: 
regulatory T cells. 
 
